FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone
|For updated information please see the FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone - 9/26/2011|
[05-31-2011] The U.S. Food and Drug Administration (FDA) is informing the public about new information1,2 that is being assessed as part of FDA's ongoing safety review of birth control pills that contain drospirenone. This review will further evaluate the risk of blood clots in women who use these products.
Facts about Drospirenone
Drospirenone is a type of female sex hormone called a progestin. Most birth control pills contain two types of hormones--estrogen and progestin. Birth control pills work by preventing the release of eggs from the ovaries (ovulation) and changing the cervical mucus and the lining of the uterus to prevent pregnancy.
A list of birth control pills that contain drospirenone is available here.
All birth control pills pose a risk of blood clots. Several epidemiological studies have reported that the risk of blood clots for women who use birth control pills containing drospirenone is higher than that for women who use birth control pills containing the progestin levonorgestrel. Other studies have not reported an increase in risk.
A blood clot that forms in a deep vein in the body is called a deep vein thrombosis (DVT). A DVT is a rare side effect of taking birth control pills. A blood clot can break loose from the vein, move through the body to the lung, and cause a serious problem in the lung, called a pulmonary embolism (PE). This can lead to death.3
Two recently published studies reported a greater risk of blood clots for women taking birth control pills containing drospirenone as compared to the risk in women taking birth control pills containing another progestin known as levonorgestrel.1,2
Previously published studies have also addressed the risk of blood clots in women using birth control pills containing drospirenone. These studies had conflicting findings--two postmarketing studies required by the FDA or European regulatory agencies did not report any difference in the risk of blood clots between drospirenone-containing products and products containing levonorgestrel or other progestins.4,5 Two other publications in 2009, however, reported that the risk of blood clots is higher in women using drospirenone-containing products than in women who use levonorgestrel-containing products.6,7
Information from these latter four studies is already presented in the Warnings and Precautions section of current labels for drospirenone-containing birth control pills. An additional large study exploring the association of blood clots with hormonal contraception has been commissioned by FDA, and results of that study are currently being finalized and reviewed.
The European Medicines Agency (EMA) announced on May 27, 2011, that it is updating the product information on oral contraceptives containing drospirenone and ethinyl estradiol regarding the risk of venous thromboembolism after review of all available data, including the same newly published data FDA is reviewing.
The FDA is currently evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone-containing birth control pills. FDA will continue to communicate any new safety information to the public as it becomes available.
- If your birth control pill contains drospirenone, do not stop taking it without first talking to your healthcare professional.
- Discuss any questions or concerns about your birth control pill with your healthcare professional.
- Know the symptoms of blood clots, including persistent leg pain, severe chest pain, or sudden shortness of breath. Contact your healthcare professional immediately if you develop any of these symptoms.
- If you smoke and are over 35 years of age, you should not take combination oral contraceptives because they increase the risk that you could experience serious cardiovascular events, including blood clots.
- Report any side effects you experience to the FDA MedWatch program using the information in the "Contact Us" box at the bottom of the page.
- Continue to follow the recommendations in the drug labels when prescribing oral contraceptive products that contain drospirenone.
- Discuss the known benefits and potential risks of drospirenone-containing products with your patients.
- Educate your patients to recognize the signs and symptoms of DVT and PE, and tell them to immediately contact their healthcare professional if they develop any of these symptoms.
- Report adverse events involving drospirenone-containing oral contraceptives to the FDA MedWatch program, using the information in the "Contact Us" box at the bottom of the page.
Two recent articles in the British Medical Journal have raised the question as to whether there is greater risk of DVT and PE in women taking combination oral contraceptives containing the progestin drospirenone as compared to the risk in women taking oral contraceptives containing the progestin levonorgestrel.1,2 These two new studies reported a two- to three-fold greater risk of venous thromboembolic events or VTEs (VTEs include DVTs and PEs) in women using oral contraceptives containing drospirenone rather than levonorgestrel.
Previously published studies have also addressed the risk of blood clots in women using birth control pills containing drospirenone. These studies had conflicting findings. Two were postmarketing studies required by the FDA or European regulatory agencies. These studies did not report any difference in VTE risk between drospirenone-containing products and products containing levonorgestrel or other progestins.4,5 However, two other publications from 2009 reported a 1.5- to 2-fold higher VTE risk in women who use drospirenone-containing contraceptives as compared to the risk in women who use levonorgestrel-containing contraceptives.6,7 Results of these latter four studies are described in the current labels for all the drospirenone-containing contraceptive products.
FDA is currently reviewing the two most recent studies and will be looking at all currently available information to assess whether there is a greater risk of VTE in women using oral contraceptives containing drospirenone. Data from an additional, large, FDA-funded, study on hormonal contraceptives is also being finalized and reviewed. This study includes over 800,000 US women and is designed to look at thrombotic and thromboembolic risks including VTE in a number of hormonal contraceptive products; results are expected later this summer. FDA will continue to communicate any new safety information to the public as it becomes available.
- Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 340:d2139.
- Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340:d2151.
- U.S. National Library of Medicine. National Institutes of Health. Health Topics monograph Deep Vein Thrombosis. Available at http://www.nlm.nih.gov/medlineplus/deepveinthrombosis.html; Accessed April 28, 2011.
- Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110(3):587-93.
- Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75:344-54.
- Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.
- Van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.
Table 1. Approved Oral Contraceptives containing Drospirenone
|Brand name||Generic name|
|Beyaz||Drospirenone, ethinyl estradiol and levomefolate calcium|
|Drospirenone and ethinyl estradiol||Drospirenone and ethinyl estradiol|
|Gianvi||Drospirenone and ethinyl estradiol|
|Loryna||Drospirenone and ethinyl estradiol|
|Ocella||Drospirenone and ethinyl estradiol|
|Safyral||Drospirenone, ethinyl estradiol, and levomefolate calcium|
|Syeda||Drospirenone and ethinyl estradiol|
|Yasmin||Drospirenone and ethinyl estradiol|
|Yaz||Drospirenone and ethinyl estradiol|
|Zarah||Drospirenone and ethinyl estradiol|
Information about Drospirenone Questions and Answers – Ongoing safety review of birth control pills containing drospirenone and a possible increased risk of blood clots
FDA Drug Safety Podcast for Healthcare Professionals: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone[ARCHIVED]
Comunicado de la FDA sobre la seguridad de los medicamentos: Actualización de la revisión de seguridad con respecto al posible incremento del riesgo de coágulos de sangre por el uso de píldoras anticonceptivas que contienen drospirenona